The Charcot-Marie-Tooth Association (CMTA) announces a $90,860 investment in a new imaging research project at UC San Diego to study how MFN2 mutations drive CMT2A progression. This CMTA Strategy To Accelerate Research (CMTA-STAR) project will equip scientists with tools to ...
Join us as we talk with Dr. Katherine Forsey, CMTA’s Chief Research Officer. Dr. Forsey shares her journey living with CMT, the impact of CMTA’s Strategy To Accelerate Research (CMTA-STAR), CMTA’s Patients as Partners in Research platform, CMTA’s Patient & ...
CMTA Films presents Jonah Berger, CMTA’s National Youth Programs Manager, as he shares his journey of living with CMTX1 (also known as CMT1X or CMTX) and the power of community. Inviting us into his home, Jonah opens up about the ...
CMTA-STAR Alliance Partner Actio Biosciences has announced that the first participant has been dosed in its Phase I clinical trial of ABS-0871, an investigational TRPV4 inhibitor being developed for CMT2C.
CMT2C is an often-severe form of CMT caused by mutations in ...
The Charcot-Marie-Tooth Association (CMTA) is excited to announce a new partnership with BILLY Footwear. When using the custom link or QR code, customers will receive 10% off their order, and BILLY Footwear will donate an additional 10% to CMTA.
BILLY Footwear ...